Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 ...

Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.

New vaccines against meningococci, pneumococci and the chikungunya virus will soon be available in Austria. This was ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

Marinomed: Marinomed Biotech AG announced that the restructuring proceedings without self-administration opened on August ...

Discover the latest Environment News in Thailand, providing comprehensive coverage on environmental issues, climate change ...

Five years after the Covid-19 pandemic China is witnessing an outbreak of the human metapneumovirus (HMPV). According to reports and social media posts, hospitals are overcrowded with infected ...

The FDA granted Priority Review to the BLA for CHIKV VLP, an adjuvanted virus-like particle (VLP)-based vaccine candidate for active immunization to prevent disease caused by chikungunya virus ...